Need more information in your inbox? Digging for more data? A premium subscription provides both full text email alerts and access to archived news.
Support Biomarker CommonsNeed more information in your inbox? Digging for more data? A premium subscription provides both full text email alerts and access to archived news. Biomarker Commons JobsLatest Biomarker NewsSearch Biomarker NewsBiomarker News Email AlertsReach your targeted audience: advertise with us |
radiotherapyCvergenX, Inc. Partners with National Cancer Institute to Develop New Test to Predict Radiation Therapy SuccessA molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company. It is being done in conjunction with the National Cancer Institute’s Clinical Assay Development Program (CADP).
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
|